AccelerAting Discovery - Prostate Cancer Foundation

AccelerAting Discovery - Prostate Cancer Foundation

Accelerating Discovery 2009-2010 Progress Report Featuring a Special Report on Our Advance on Washington Table of Contents Founder/CEO Letter 1 ...

4MB Sizes 1 Downloads 28 Views

Recommend Documents

Global Enterprise & Partnership - Prostate Cancer Foundation
Pharmaceuticals, a Johnson & Johnson company),. Xgeva (Amgen) and Jevtana ..... AND GLOBAL CLINICAL. TRIALS NETWORk DELI

FIFTeen YeArs oF progress - Prostate Cancer Foundation
Progress rePort. Wasserman, Comden, Casselman & pearson, LLp. Thomas and emily Weisel. Will Weinstein. John F. Welch, Jr

Prostate Cancer 2017: The Coming Sea-Change of Prostate Cancer
Aug 17, 2017 - Prostate Cancer 2017: The Coming Sea-Change of Prostate Cancer Care | Simms/Mann-UCLA Center for Integrat

Prostate Cancer Foundation Releases Its First Annual Report to the
Chairman. Prostate Cancer Foundation. Merv Adelson. Chairman. East West Venture Group. Jim Allchin. Group Vice President

Thank you - Prostate Cancer UK
The Milly Apthorp Charitable Trust. - The Open Agency. - The Rangers Charity Foundation. - The Simon Gibson Charitable T

banana bread - Prostate Cancer UK
Angela Hartnett MBE. BANANA BREAD. Makes one loaf (12 slices). Ingredients. • 100g Sultanas. • 75ml rum. • 4 Small

Unproven Therapies in Prostate Cancer
Theranos was performing tests on patients without having published peer-reviewed research – a cardinal science – and

strawberry shortcakes - Prostate Cancer UK
STRAWBERRY SHORTCAKES. Makes 8. Ingredients. For the Shortcakes: • 325g plain flour. • ½ tsp salt. • 1 tbsp bakin

uncorrected proof - Cancer Discovery
Jun 1, 2017 - Corresponding Authors: Ethan Cerami, Dana-Farber Cancer Institute, ..... Embry onal tumor. Other. Soft tis

research brief - Cancer Discovery
Dec 3, 2014 - Majewski6,7, David A. Dyment1, A. Micheil Innes8, Kym M. Boycott1, Lisa ..... Farmer H, McCabe N, Lord CJ,

Accelerating Discovery 2009-2010 Progress Report

Featuring a Special Report on Our Advance on Washington

Table of Contents Founder/CEO Letter


The Promise of Personalized Cures


Creativity & Innovation for Cures


Reaching Patients & Families 9 Special Report: PCF’s 2010 Advance on Washington


A Special Thank You


Events for Cures


Appeal for Support 


Donation Opportunities


Financial Statements


Partners for Progress


Board of Directors & Leadership Team


The Prostate Cancer Foundation (PCF) is a foundation without borders. Our advocacy for increased government and private support for prostate cancer research programs has helped build a global research enterprise of nearly $10 billion and made PCF a respected source of KNOWLEDGE, INTEGRITY and HOPE for more than 16 million men and their families who are currently afflicted with the disease. PCF is accelerating the most promising research and discovery of better treatments and cures for prostate cancer. Since 1993, PCF has raised more than $415 million and funded more than 1,500 research projects at nearly 200 institutions in 12 countries. PCF researchers are fast-forwarding breakthroughs in prostate cancer research that will enable us to achieve our vision for a world where no man suffers or dies from this disease.

About the Cover: A Rosetta Stone for Prostate Cancer PCF-supported researchers at the University of Michigan identified 24 types (clonotypes) of prostate cancer; 23 are caused by specific gene fusions (erroneous pairings of genetic codes) and one is initiated by an overexpression of a gene called SPINK1. Like a Rosetta Stone, this historic decoding of prostate cancer opens a new world of understanding and will accelerate discovery of better early diagnostics and treatments. It permits differentiation between non-life-threatening and aggressive forms of prostate cancer and enables clinicians to match patients to treatments that are most effective for their particular clonotype. The discovery represents a pivotal moment in PCF’s mission to cure more and overtreat less, bringing an end to death and suffering from prostate cancer.

About the Graphs: PCF’s expertise enables us to maintain revenue levels despite economic fluctuations. Agility allows us to fund crucial research immediately and ensure progress.

5-Year Revenue History

2009 Spending


Per Dollar

40 35



Prostate Cancer Research Mission

$37.2 $33.2


Research Grants & Programs Support





Public Education & Advocacy

25 20 15




5 0









Dear Friends, The exciting news from the front lines of cancer research is that the pace of scientific progress has accelerated, delivering more results in prostate cancer research in the past 12 months than in the past decade. This is translating into more advances and hope for the more than 16 million men and their loved ones affected by prostate cancer around the world. In the field of medical research against deadly diseases, prostate cancer stands out as an area delivering promising results for better and earlier diagnosis so we can cure more and overtreat less. Our ability to reach this historic point in cancer research is built on the generosity of the more than 170,000 donors who have helped us raise over $415 million for game-changing research since 1993. We reached several important milestones in 2010. The discovery of 24 types of prostate cancer by PCFfunded researchers at the University of Michigan is a breakthrough finding. As a Rosetta Stone for prostate cancer research, this important advance provides the key to one day being able to prescribe highly personalized treatment plans. The Michigan team’s gene fusion research identifies specific targets, so

we can better decode cancer markers and distinguish between life-threatening tumors and indolent varieties that do not require aggressive treatments. More great news is the approval of two new drugs for prostate cancer in 2010, Provenge® (immunotherapy), and Cabazitaxel (chemotherapy), and the pending approvals of Denosumab (fracture prevention) and Abiraterone (hormone therapy). Provenge is the first immunotherapy shown to be effective in extending the lives of men with advanced prostate cancer. It is an important proof of concept demonstrating that we can harness the power of the body’s own immune system to fight cancers—a scientific concept that PCF began funding more than 10 years ago. PCF is pursuing additional research so we can better understand how immunotherapy works and why it is effective for some patients and not for others. Cabazitaxel is an advance in secondary chemotherapy for advanced prostate cancer. This new agent is effective in men who become resistant to Docetaxel, a long-preferred chemotherapy. Furthermore, Denosumab, a drug used to maintain bone strength 2009-2010 progress report 1

and prevent fractures in men undergoing androgen deprivation therapy (ADT), represents an important advance for improved survivorship. Following successful completion of Phase III clinical trials, Abiraterone is in the final evaluation and decision process at the Federal Drug Administration (FDA). It blocks the production of testosterone, the fuel for prostate cancer progression, and is targeted for use in men who have become resistant to current androgen deprivation drugs such as Lupron. It is already being cleared by the FDA for use on a case-by-case basis for patients who have no other treatment options. Abiraterone was initially discovered at the Institute of Cancer Research in London. PCF-funded investigators participated in its development and researched how it works. A fifth potential new drug on the horizon for patients is Ipilimumab, another promising immunotherapy agent. It is currently pending approval at the FDA for melanoma patients and is in Phase III trials for prostate cancer patients with metastatic hormonerefractory disease. PCF funded much of the fundamental science and early clinical investigations for this promising treatment. In addition to five new drug treatments, the stem “cell of origin” for human prostate cancer was identified. For decades, scientists believed that prostate cancer stem cells originated in luminal cells that line the top of the tiny ducts of the prostate. However, this year, UCLA researchers supported by PCF showed that basal cells, found at the base of the prostate ducts, are the source for prostate cancer. This finding directs researchers to the cancer’s source and will enable them to better understand the primary mechanisms for prostate cancer and identify new treatment targets. We urgently need to build on this progress, which produces a host of new opportunities to turn lab discoveries into new and more effective medicines. In 2009, PCF recorded its third-highest year for contributions despite the global recession. The $33.2 million you donated helped to fund 10 new 2 2009-2010 progress report

Creativity Awards and allowed us to realize our goal of supporting more than 50 Young Investigators by the close of 2010. These new research awards are in addition to our support of 15 existing multi-million dollar, multi-year Challenge Award commitments and sponsorship of the Prostate Cancer Clinical Trials Consortium (PCCTC) that is partnered with the Department of Defense. Since 2005, the PCCTC has enrolled more than 2,400 patients in clinical trials that deliver innovative new treatments to patients. By the second half of 2010, 12 new Phase I and Phase II clinical trials were in the pipeline and seven new protocols were activated by the Consortium. PCF advocates for more research in addition to funding it. In September 2010, PCF moved its 17th Annual Scientific Retreat to Washington, D.C. as part of a major Advance on Washington. In conjunction with three other prostate cancer organizations, this effort provided a week of scientific, advocacy, and government outreach meetings and events that stimulated much-needed media awareness and government attention in Congress and at the White House. We are pleased to include a special report on these activities. With your continued support, we will further our progress. We will find an end to prostate cancer. Thank you for helping us make it happen. With sincere appreciation,

Mike Milken

Founder and Chairman

Jonathan W. Simons, MD President and Chief Executive Officer David H. Koch Chair

the promise of Personalized cures A Reality Within Reach In 2010, prostate cancer research achieved an historic number of milestones. The progress made in the past year accelerates fundamental discoveries that will translate into cures. We are closer than ever to realizing our vision of delivering personalized cures for every patient who is diagnosed.

A “barcode” approach to prostate cancer treatment will include a variety of data points specific to each individual patient.

Decoding Cancer through Gene Fusions PCF-funded researchers at the University of Michigan, led by Arul Chinnaiyan, MD, PhD, made a landmark discovery by identifying 24 types of prostate cancer. Of these, 23 are indicated by distinct gene fusions, and one is defined by an enzyme called SPINK1. Many of these gene fusions could disclose the Achilles’ heel of a distinct set of prostate cancers and markers for disease aggressiveness. Investigations to determine the function of each gene fusion will be essential to delivering new medicines designed to target specific types of prostate cancer. University of California, San Diego researchers are building on the Michigan discovery by investigating the molecular mechanisms that mutate into recurrent

gene fusions. The team, led by Michael Rosenfeld, MD, has developed a process that can artificially create these fusions in normal prostate cells in the lab to screen for compounds that prevent cancer. Memorial Sloan-Kettering Cancer Center scientists, funded by PCF, identified a genomic signature of RNA and DNA codes for men who may not need surgery or radiation and those who most likely need aggressive treatment. With these signatures, doctors can potentially talk to their patients about whether or not they need additional therapy following surgery. The purpose of this continuing research is to integrate genomic information into a “barcode” for each patient that would match them with personalized, predictive and optimal treatments. 2009-2010 progress report 3

Discovering the Stem Cell of Prostate Cancer

For the first time in oncology, activating a patient’s immune system prolonged the survival of a patient with an advanced solid tumor. This new cell-based therapy is proof of principle that the immune system can be harnessed against advanced disease, even after cancer has emerged and spread. Today, PCF-supported scientists are at work on the next generation of vaccines and antibodies that re-task the immune system to unleash tumor-fighting cells.

Advancing Beyond the PSA Debate with Liquid Biopsies

Basal cells do not express PSA (prostate-specific antigen), but have the capacity to generate malignant glands (seen above in reddish-brown) expressing PSA. (Image courtesy of UCLA)

Owen Witte, MD, at the University of California, Los Angeles, made a seminal discovery that was published in the journal Science this year. The paper’s authors identified prostate basal stem cells (found at the base of the prostate ducts) as the prostate cancer cell of origin, a surprise to the field that speculated only epithelial cells (that line the prostate ducts) could be the cell of origin. This finding elevates the level of stem cell knowledge for the research community and will aid in the discovery of new targeted medicines. They will be aimed at exterminating the elusive prostate cancer stem cell, a therapy-resistant cell capable of regenerating an entire tumor.

Harnessing the Power of the Immune System Since 1993, PCF has funded innovative prostate cancer research aimed at harnessing the immune system to fight prostate cancer. In fact, PCF funded early dendritic cell based research, including the first research ever conducted on Provenge (sipuleucel-T). In April 2010, the FDA approved Provenge as the first immunotherapy for metastatic prostate cancer. 4 2009-2010 progress report

Daniel Haber, MD, PhD, a PCF Challenge Award recipient, and his team at Massachusetts General Hospital is speeding the delivery of a liquid biopsy for prostate cancer patients. The newest device features a 10 to 1000 times greater detection rate for a single circulating tumor cell (CTC) in a drop of blood. This scalable device increases the probability of a CTC to interact and adhere to the walls of the capture device. This data will enable doctors to tell how aggressive the cancer is and how fast it is growing.

Fighting Androgen DeprivationResistant Cancers The androgen receptor is one of the central drivers behind prostate cancer cell growth. Advances in blocking androgen receptor signaling are urgently needed for patients whose initial response to traditional androgen-blocking drugs is followed by a relapse from resistant cells. Thanks to $14.6 million in new seed funding from PCF, we now have two oral androgen receptor-blocking antagonists that can actually put patients back into remission: Abiraterone (Johnson & Johnson) and MDV3100 (Medivation, Inc.). In Phase III clinical trials of Abiraterone, a PCFsupported team of clinical scientists in London, New York and San Francisco, reported a significant survival advantage in androgen deprivation-resistant prostate cancer. Abiraterone is an inhibitor of the enzyme CYP17 which is critical for the synthesis of intratumoral androgens. MDV3100, another novel antiandrogen, is in Phase III trials under the leadership

is testing new androgen inhibitors and discovering new resistance mechanisms with the goal of further improving patient treatment.

Improving Survivorship

Dr. Peter Nelson at Fred Hutchinson Cancer Research Center at the University of Washington is collaborating with PCF-funded scientists and investigating Abiraterone resistance in patients.

of a PCF-supported team at Memorial SloanKettering Cancer Center. Biomarkers for patient selection and rapid determination of outcomes are embedded in both of these studies. For example, CTC measurements are being tested as early indicators of remissions. New imaging techniques are being qualified as earlier biomarkers of treatment success. Collaboration between Challenge Award recipients Steven Balk, MD, PhD, at Beth Israel Deaconess Medical Center, Peter Nelson, MD, at Fred Hutchinson Cancer Research Center, and investigators at Harvard, studied the inevitable development of Abiraterone resistance. Additional androgen metabolism inhibitors are being tested in combination with Abiraterone to eliminate residual androgen and disease recurrence. Furthermore, Trevor Penning, PhD, at the University of Pennsylvania discovered five new compounds that inhibit androgen synthesis differently than Abiraterone. His team

Challenge Award recipients Matthew Smith, MD, PhD, of Massachusetts General Hospital, Michael Pollak, MD, of McGill University, and Stephen Freedland, MD, of Duke University are focused on understanding and treating the side effects of androgen deprivation therapy (ADT). One significant outcome was the successful Phase III clinical trial of Denosumab that reported a reduction in bone fractures caused by ADT. An additional effect of this therapy is the onset of metabolic syndrome, a Type II diabetes-like disorder. Epidemiology studies show reduced incidence of prostate cancer in men taking Metformin for diabetes. A clinical trial of Metformin in patients receiving ADT, to prevent metabolic syndrome, will commence soon. As a result of the rapid acceleration of discovery in prostate cancer research and greater participation in our clinical trials, we envision a day when every man will have access to better diagnostics that will enable physicians to prescribe treatments matched perfectly to their specific cancer type.

2009-2010 progress report 5

CREATIVITY & INNOVATION FOR CURES Much of the progress that has been made in our efforts to end prostate cancer is the direct result of PCF’s commitment to funding innovative ideas and high-risk yet highreward projects that are typically left unfunded by more traditional, governmentsupported programs. Cory Abate-Shen, PhD (2009) Columbia University Medical Center The Gordon Becker Creativity Award Gustavo Ayala, MD (2010) Baylor College of Medicine Brendan Curti, MD (2010) Providence Portland Medical Center Adam Dicker, MD, PhD, Karen Knudsen, PhD (2009) Kimmel Cancer Center, Thomas Jefferson University The Charlie Wilson Creativity Award

The more we learn about prostate cancer, its origins and mechanisms, the more complex the remaining challenges become. PCF’s Creativity Awards support game-changing ideas, accelerating the world’s most promising research. PCF also invests in Young Investigators to build human capital and support a robust research enterprise. These grants are designed to attract the world’s brightest young scientific minds and encourage them to dedicate their research careers to solving the problem of prostate cancer. Our commitment to creativity and innovation engages intellectual power and resources to find solutions from entirely new concepts and advances in immunotherapy, biomarkers like gene fusions and circulating tumor cells, and new targeted medicines.

2009 and 2010 Creativity Awards Twenty-two new Creativity Awards were selected from 457 applications representing more than 100 institutions worldwide. Historically, 70 percent of these awards have leveraged additional multi-year funding from government, biotech and pharma. These new grants represent a total new commitment of $4.6 million. 6 2009-2010 progress report

Jennifer Doll, PhD (2010) NorthShore University HealthSystem Research Institute Charles Drake, MD, PhD (2010) The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins The Evensen Family Creativity Award Shelton Earp, MD (2009) University of North Carolina The Michael Vinecki Creativity Award Barbara Graves, PhD (2009) University of Utah David Heber, MD, PhD (2009) University of California, Los Angeles Towia Libermann, PhD, Alan Rigby, PhD (2009) Beth Israel Deaconess Medical Center Harvard Medical School James Marshall, PhD (2010) Roswell Park Cancer Institute David Nanus, MD (2009) Weill Cornell Medical College The Dan Fogelberg Creativity Award Nora Navone, MD, PhD (2010) The University of Texas MD Anderson Cancer Center

William Oh, MD (2010) Mount Sinai School of Medicine Pier Paolo Pandolfi, MD, PhD (2009) Beth Israel Deaconess Medical Center Harvard Medical School Renata Pasqualini, PhD (2010) The University of Texas MD Anderson Cancer Center Kenneth Pienta, MD (2010) University of Michigan Matthew Rettig, MD (2010) University of California, Los Angeles Matthew Smith, MD, PhD (2010) Massachusetts General Hospital Muneesh Tewari, MD, PhD (2009) Fred Hutchinson Cancer Research Center and University of Washington The Arnie’s Army Creativity Award John F. Ward, MD (2009) The University of Texas MD Anderson Cancer Center Scott Williams, MD (2010) Peter MacCallum Cancer Centre, Australia

2010 Young Investigator Awards With 27 new Young Investigators added to 23 from 2008, PCF is now funding 50 projects led by young and innovative researchers whose backgrounds include computer science, molecular biology, pharmacology, radiation oncology, medical oncology and endocrinology. Recipients receive three years of funding to test transformational research questions for prostate cancer patients. The 2010 Young Investigator Awards represent a $6.1 million investment in the global cancer research community. Himisha Beltran, MD Weill Cornell Medical College The LeFrak Family Young Investigator Award Justine Bruce, MD University of Wisconsin Carbone Cancer Center In Honor of Our Soldiers and the Department of Defense Congressionally Directed Medical Research Program for Prostate Cancer

Brett S. Carver, MD Memorial Sloan-Kettering Cancer Center The David H. Koch Young Investigator Award Robert Den, MD Kimmel Cancer Center, Thomas Jefferson University The Ben Franklin Young Investigator Award Felix Feng, MD University of Michigan The Republic of Tea Young Investigator Award David S. Finley, MD University of California, Los Angeles The Lynda & Stewart Resnick Young Investigator Award Isla Garraway, MD, PhD University of California, Los Angeles The Winter Vinecki Young Investigator Award, sponsored by Lori Milken Hans Hammers, MD, PhD Johns Hopkins University Medical School The William Bikoff Young Investigator Award Daniel Hamstra, MD, PhD University of Michigan The Charles Dolan & Mark Walter Young Investigator Award Julia Hayes, MD Dana-Farber Cancer Institute The Ressler-Gertz Family Foundation Young Investigator Award Hannelore Heemers, PhD Roswell Park Cancer Institute The Heritage Medical Research Institute Young Investigator Award Andrew C. Hsieh, MD University of California, San Francisco Through the generosity of an anonymous donor Joshua Lang, MD, MS University of Wisconsin Carbone Cancer Center The Dendreon Corporation Young Investigator Award Stanley Liauw, MD University of Chicago The Brookdale Foundation Young Investigator Award

2009-2010 progress report 7

Christopher Maher, PhD University of Michigan The Stewart Rahr Young Investigator Award

Philip Saylor, MD Massachusetts General Hospital The Stewart Rahr Young Investigator Award

Ram S. Mani, PhD University of Michigan The Stewart Rahr Young Investigator Award

Jennifer Schutzman, MD, PhD University of California, San Francisco The Richard N. Merkin, MD Young Investigator Award

Neil Martin, MD, MPH Dana-Farber Cancer Institute and Brigham and Women’s Hospital The David Epstein Young Investigator Award

Jay Shendure, MD, PhD University of Washington The Lowell Milken Young Investigator Award

Kenneth May, MD, PhD Dana-Farber Cancer Institute The David Epstein Young Investigator Award

Neha Vapiwala, MD University of Pennsylvania The Emilio Bassini Young Investigator Award

Prior to the start of our 17th Annual Scientific Retreat, PCF Young Investigators, mentored by PCF-supported scientists, spent a day identifying new challenges in our scientific agenda and innovative approaches that may deliver research solutions and cures.

Nicholas Mitsiades, MD, PhD Baylor College of Medicine Akash Patnaik, MD, PhD Beth Israel Deaconess Medical Center The Stewart Rahr Young Investigator Award Edwin Posadas, MD University of Chicago The Stewart Rahr Young Investigator Award

Amina Zoubeidi, MSc, PhD University of British Columbia Vancouver Prostate Centre The Durden Foundation Young Investigator Award Amado Zurita, MD The University of Texas MD Anderson Cancer Center The David & Judy Fleischer Young Investigator Award

For complete information on PCF’s 2009 and 2010 grant recipients and their projects, and to learn more about PCF research initiatives and strategies, scan this QR code with your smart phone, or go to: 8 2009-2010 progress report

REACHING PATIENTS & FAMILIES PCF is committed to providing men and their families the best information available on the current best practices for treatment and the latest research findings. We fulfill this task by leveraging the benefits of online and social media, in addition to traditional methods of communication.

A New Web Presence with In 2009, PCF’s communications team undertook an extensive upgrade of Using input collected from surveys of patients, caregivers, researchers and other medical professionals, a new website was launched in April 2010. The new site features: • Enhanced user interface and navigation • Daily news feeds from Reuters and HealthDay • Patient information provided according to patient disease status • Rich video content • Expanded survivor and researcher stories A marketing program, designed to provide urologists with patient information materials and drive new visitors to the website, was launched in September, 2010. The first wave of materials was mailed to practitioners in the New York and Los Angeles metropolitan areas. This program will be monitored and assessed for further implementation in the coming year.

awareness program for on widely-read WebMD® and a new prostate cancer blog,, are also helping to introduce patients and their caregivers to PCF, its mission and information resources.

Reaching a Disproportionately-Affected Population of Men Understanding that African-American men are 60 percent more likely to be diagnosed with prostate cancer and 2.4 times more likely to die from it, PCF identified an urgent need to better reach this group of men with the important message of early detection and treatment. In 2009, PCF teamed with Grammynominated R&B artist and survivor Charlie Wilson and the Black Barbershop Health Outreach Program (BBHOP). Through his concert tours and media coverage, Wilson has delivered this important health message to more than three million American men and their families. PCF also provided BBHOP with a Communications Grant to support its 50 City Tour, bringing information on prostate cancer, diabetes and hypertension to inner-city African-American communities. To support these efforts, PCF produced a special brochure, Prostate Cancer: Straight Talk for African-American Men and Their Families, available at

The Power of Social Networking In 2009, PCF launched several social media initiatives. Within 12 months, the number of PCF Facebook friends grew by more than 1,000 percent to over 8,000. Since January 2010, PCF has attracted more than 1,500 Twitter followers. These tools deliver breaking news and information to PCF followers in a highly-visible and cost-effective manner. A pilot 2009-2010 progress report 9

SPECIAL REPORT PCF’s 2010 Advance on Washington To increase awareness and promote government engagement, PCF moved the 17th Annual Scientific Retreat from Lake Tahoe to Washington, D.C. in coordination and partnership with other leading prostate cancer organizations.

PCF mobilized the meeting and spearheaded a

nation’s leaders. During the press conference, PCF

cooperative effort with ZERO—The Project to End

issued a Five-Point Call to Action for ending prostate

Prostate Cancer, the

cancer that was

Prostate Health

endorsed by 14 U.S.

Education Network

prostate cancer

(PHEN) and the Black


Barbershop Health

PCF representatives

Outreach Program

were featured guest

(BBHOP). The vision

speakers at ZERO’s

was to create a critical

Advocacy Summit, the

mass of events and


meetings during

Prostate Cancer

September, National

Disparities Meeting

Prostate Cancer

sponsored by PHEN,

Awareness month.

and at the

The Advance on

Congressional Black

Washington was a

Caucus Meeting. The

highly visible and

BBHOP, with

integrated program of

sponsorship from PCF,

media events and

concluded the week by

meetings focused on

conducting special

prostate cancer

informational events

research, discovery,

and health screenings

advocacy, healthcare

for prostate cancer,

disparities and overall

hypertension and


diabetes at 16 inner-

With more than 1,000 scientists, specialists,

city barbershops in Washington, D.C. and Baltimore.

advocates and patients converging on our nation’s

The 17th Annual Scientific Retreat was the largest to

capital, PCF and the three partnering organizations

date and received high marks for its content and

were able to share program speakers and hold a joint

context. Prostate cancer researchers and patients

press conference. This effectively advanced our

will benefit from the Advance on Washington for

message for increased government support to our

months to come.

10 2009-2010 progress report

PCF’s Five-Point Call to Action 1. Increase the NCI’s $5 billion annual budget to accelerate basic and treatment sciences research for human prostate cancer from $294 million to a transparent $400 million. 2. Increase the appropriation for the Congressionally Directed Medical Research Program for Prostate Cancer at the Department of Defense to $120 million from $80 million.

In the U.S. alone, more than $1 billion is spent each year on overtreating men who are diagnosed with non-life-threatening varieties of prostate cancer, while more than 32,000 will die from the aggressive types of this cancer in 2010. By 2015, the number of new annual cases is predicted to rise beyond 300,000 from 218,000 in 2010, making prostate cancer the number one men’s health crisis in America. With recent progress, prostate cancer is at an historic turning point. We believe we can soon reach our goal of curing more and overtreating less, ending death and suffering from this disease while returning billions of dollars to the American economy. However, we cannot let up on government and private investment for a cure. The Five-Point Call to Action issued to our nation’s leaders is designed to free us from the burden of prostate cancer. The Call to Action is endorsed by PCF and 13 other prostate cancer organizations. • • • • • • • • • • • • •

American Urological Association The AUA Foundation Black Barbershop Health Outreach Program Malecare Prostate Cancer Support Men’s Health Network National Alliance of State Prostate Cancer Coalitions Prostate Cancer International Prostate Conditions Education Council Prostate Health Education Network The Prostate Net US TOO International Women Against Prostate Cancer ZERO—The Project to End Prostate Cancer

3. Establish an Office on Men’s Health (OMH) in the Department of Health and Human Services equivalent to the Office on Women’s Health (OWH), established in 1991. 4. Create a Prostate Cancer Scientific Advisory Board for the Office of the Chief Scientist at the FDA to accelerate real-time sharing of the latest research data and accelerate movement of new medicines to patients. 5. Create human capital by launching more careers of the best and brightest scientists in the U.S. to solve the prostate cancer problem. During the Advance week, Senate Bill S.3775—The Prostate Cancer Act of 2010—was introduced by Senator Jon Tester from Montana (pictured below). It calls for greater coordination and inter-agency research collaboration, and greater reach to rural patients. At the close of September, House Bill H.R. 6389, supporting prostate cancer research and education, was introduced by Representative Edolphus “Ed” Towns from New York.

2009-2010 progress report 11

Clockwise from top left: Jean Fogelberg speaks at PCF’s Survivors Breakfast • Tom Farrington of the Prostate Health Education Network and Dr. Stanley Frencher of the Black Barbershop Health Outreach Program answer questions at the Advance on Washington joint press conference • Dr. William Nelson, Senator John Kerry (D-MA) and PCF Chairman Mike Milken at the Congressional Reception on Capitol Hill • Dan Zenka, PCF VP of Communications, opens the Survivors Breakfast with PCF Young Investigators • Dr. Charles Sawyers shares his research at PCF’s Scientific Retreat • Movember founder

12 2009-2010 progress report

Adam Garone addresses attendees at PCF’s Retreat • Mike Milken and Senator Jeff Sessions (R-AL) at the Congressional Reception • PCF donor Stewart Rahr discusses the latest in scientific advances with PCF Young Investigators • PCF Young Investigators collaborate on innovative research prior to the opening of the Scientific Retreat • U.S. Speaker of the House, Nancy Pelosi and Mike Milken speak to members of the press on Capitol Hill • PCF President and CEO, Dr. Jonathan Simons speaks at the press conference • Reverend Rosey Grier, PCF director, and Senator Jeff Sessions meet on Capitol Hill

2009-2010 progress report 13

A special thank you The Prostate Cancer Foundation would like to thank everyone who has supported us during the past seventeen years. We gratefully acknowledge the following individuals, foundations, corporations and others who have given at least $5,000 since our founding.

Founders ($50,000,000+) Milken Family Foundation

Founders’ Circle ($2,000,000 to $49,999,999)

Anonymous (4) Leon and Debra Black Bristol-Myers Squibb Company Jamie B. Coulter The Charles Evans Foundation David H. and Julia Koch Thomas H. Lee and Ann Tenenbaum Carl Lindner Lowell Milken Michael and Lori Milken The News Corporation Foundation Stewart and Lynda Resnick Safeway, Inc. Sanofi-Aventis M. Shanken, Chairman/ M. Shanken Communications, Inc. Stephen and Elaine Wynn

Leadership Circle ($1,000,000 to $1,999,999)

Anonymous (5) Abbott Laboratories Baume & Mercier Co. Conde Nast Publications, Inc. Charles F. Dolan William L. Edwards Edward P. Evans Foundation Andrew S. Grove Kern Family Fund Sidney Kimmel Rush Limbaugh The Lincy Foundation The Honorable Earle I. and Carol Mack Major League Baseball Charities, Inc. Charles N. Mathewson Foundation The Craig and Susan McCaw Foundation Richard N. Merkin, MD Movember, Inc. James W. Newman Kerry Packer Nelson and Claudia Peltz Ronald O. Perelman PGA Tour Charities, Inc Cliff and Debbie Robbins Julian H. Robertson, Jr. William A. Schwartz Terry and Jane Semel David E. and Beth Kobliner Shaw Thomas Spiegel Lawrence J. and Joyce Stupski Tarnopol Family Foundation, Inc. Wade F.B. Thompson Charitable Foundation Ted and Dani Virtue Martin and Pamela Wygod Stanley and Barbara Zax

Benefactors ($500,000 to $999,999) Anonymous (4) Joseph and Annette Allen Robert K. Barth

14 2009-2010 progress report

Eric D. Becker Bill and Ann Bresnan Foundation, Inc. The Bunker Foundation Ronald W. Burkle Winston H. Chen, Ph.D. Stephen and Chantal Cloobeck Lawrence J. Ellison R. Christian B. Evensen Sue Gin D. Wayne and Anne Gittinger Golfers Against Cancer The Greenspun Family Foundation Guggenheim Investment Management, LLC Richard and Deborah Justice Peter Karmanos, Jr. C. Michael and Elizabeth Kojaian Richard S. and Karen LeFrak Charitable Foundation Jeffrey A. Marcus Joy and Jerry Monkarsh Family Foundation Gordon E. Moore Bruce and Jeannie Nordstrom Novartis Pharmaceuticals Corporation Stewart and Carol Rahr Lewis and Peg Ranieri Brian and Patricia Reynolds William A. Richardson Richard V. and Ellen Sandler, Esq. Mickey and Karen Shapiro Lester and Sue Smith Foundation Edward M. Snider Sportsgrants, Inc. Stuart Subotnick Yahoo!

Patrons ($250,000 to $499,999)

Bayer Corporation Brian and Kathleen Bean Charles and Michelle Becker Marc R. Benioff Bloomberg LP The Eli and Edythe Broad Foundation James and Patricia Cayne L. John Doerr The Durden Foundation, Inc. David and Marsha Ederer David J. Epstein Ralph and Cynthia Finerman David and Judith Fleischer Gen-Probe Incorporated The Gillette Company Howard Gittis Phillip and Lyn Goldstein Harkins Charitable Gift Fund Heinz North America Steven and Tomisue Hilbert The R.D. and Joan Dale Hubbard Foundation Ray and Ghada Irani Peter W. Janssen Michael Jordan Kissick Family Foundation Charles G. Koch

Herb and Natalie Kohler Robert A. Kotick Kovler Family Foundation Lamkin Corporation Gary and Tina Lowenthal F. W. McCarthy Foundation Medical Research Agencies of America Richard Mejasich MidOcean Partners Jay and Elaine Moorin, Alain and Iris Schreiber, and ProQuest Investments Joseph Neubauer Joel M. Pashcow Allen and Madeleine Paulson Sandra and Lawrence Post Family Foundation Leonard and Louise Riggio Marc J. and Carolyn Rowan Gene and Marianne Salmon The John F. Scarpa Foundation Melvin and Bren Simon Charitable Foundation No.1 Joseph and Diane Steinberg 1992 Charitable Trust Paul and Elle Stephens Sterling Equities Robert & Jane Toll Foundation Warren and Jale Trepp Clyde T. Turner Vadasz Family Foundation Varian Medical Systems, Inc. Robert and Angela Voss The Wagner Family Foundation Dennis and Phyllis Washington Foundation Gary and Karen Winnick

Partners ($100,000 to $249,999)

Anonymous (1) William and Donna Acquavella The G. Chris Andersen Family Foundation Phillip and Nancy Anschutz Ambassador George L. Argyros, Sr. Arnie’s Army Battles Prostate Cancer Atlanta Hawks The Lynn Aymar Family Foundation Chris and Tory Bagdasarian Charles F. Baird, Jr. Robert Baldwin Ron and Judy Baron The Cecile and Fred Bartman Foundation Braman Family Foundation Gary S. Broad The Brookdale Foundation John and Barbara Burns August A. Busch, IV California State Council of Laborers Callaway Golf Sales Company Ely R. Callaway Wayne Calloway CAO International, Inc. Dick and Lisa Cashin

Cendant Corporation John and Jennifer Chalsty Max C. Chapman, Jr. Chicago White Sox Jerry and Adrianne Cohen James H. Coleman Robert D. Collins Fund Concern Foundation The Carole & Robert Daly Charitable Foundation Neil P. DeFeo Ronald M. DeFeo Thomas and Gun Denhart James and Kristin Dolan Dunwoody Senior Men’s Golf Association Jeremy D. Eden Lee and Daniele Einsidler Don Engel Ernst & Young LLP Robert S. Evans Faith, Love, Hope, Win Foundation William F. Farley M. Anthony and Anne Fisher Sidney E. Frank Friendship Foundation, Inc. Richard S. Fuld, Jr. The David Geffen Foundation Richard and Phyllis Gelb Genentech Foundation Eric and Anne Gleacher Robert B. and Pamela Goergen Thomas and Holly Gores Greenbriar Golf Association Orland S. Greene Wayne and Janet Gretzky The Sam and Sarah Grossinger Foundation Martin and Audrey Gruss Richard B. Handler Joseph W. Harch J. Ira and Nicki Harris Thomas O. Hicks Hilton Hotels Corporation Leo Hindery, Jr. Thomas and Virginia A. Hughes Hugo Boss Fashions, Inc. Jon and Karen Huntsman Carl and Gail Icahn Mel and Terry Karmazin David Karpol Solomon Kerzner Michael and Jena King W. C. Klintworth Knowledge Universe Laborers’ International Union of North America The Leeds Family Foundation W. Howard and Mary Lester Robert Levin Solomon and Rosie Lew Peter B. Lewis William and Phyllis Mack Margaritaville Holdings, LLC Peter and Leni May Bruce R. and Jolene M. McCaw Fund

George A. Mealey Keith Meister Robert A. Meister Avram Miller S. Leslie and Barbara Misrock Kenneth and Julie Moelis Moore Family Foundation John and Rebecca Moores Marc and Jane Nathanson Linden Nelson George and Sandra Norcross John and Sally Nordstrom OSI Pharmaceuticals Palermo Ravich Family Foundation Rick Pitino Bruce I. Raben Mark Redmond Annual Golf Tournament Sumner and Paula Redstone The Republic of Tea Allan V. Rose Lew Rothman The Rachel and Lewis Rudin Family Foundation, Inc. Larry W. Ruvo Haim and Cheryl Saban San Francisco Giants Stephen L. Schwartz Stephen A. Schwarzman Brett T. Setzer David and Janelle Shaffer J. Gary and O.J. Shansby Foundation Silent Partners Inc. Shoes for Crews, LLC Jeffrey and Lisa Silverman Skull Creek Development Eric and Susan Smidt Don Soffer David M. Solomon Martin & Toni Sosnoff Foundation Alex G. Spanos The John R. & Inge P. Stafford Foundation Joe Fred Starr Avy and Marcie Stein Ernest E. Stempel The Stern Family Foundation Roger and Susan Stone Swing for the Cure Marty Tenenbaum Laurence and Billie Tisch Tom and Diane Tuft Barbara Tyson Van Van Auken Ira Walker Jay L. and Linda G. Wallberg Raul and Vicki Walters Wasserman, Comden, Casselman & Pearson, LLP Will K. Weinstein Thomas and Emily Weisel John F. Welch, Jr. Herbert A. Wertheim Gregory White Jim and Kim Williams Zapolin Transactional Ventures, Inc. Sam Zell Selig Zises

Associates ($50,000 to $99,999)

Anonymous (5) AJA Charitable Fund Robert and Jodi Allardice Edward C. Allred Altadis USA, Inc. Kenneth Ambrecht Matthew Arcella Eric J. Aronson Arthur J. Gallagher & Co.

Michael and Marlene Aufrecht Facundo L. Bacardi Mr. & Mrs. Robert Baker Family Foundation Robert Bales Roger Barnett Frank and Kathy Baxter Erin and Douglas Becker Samuel Belzberg Marshall Bennett Ken Berg Martin and Phyllis Berman Robert and Catherine Beyer Frank and Carol Biondi, Jr. The Stanley & Joyce Black Family Foundation Jim & Diane Blair Charitable Foundation Dan Blumenthal Boston Red Sox Jerry Brassfield Shann Brassfield Gresham T. Brebach, Jr. Steven A. Burd Frank Caufield Century Golf Partners Management Ray and Patti Chambers Alfred and Kathryn Checchi Marshall and Maureen Cogan Robert and Beverly Cohen Family Foundation Countrywide Credit Industries Howard Cox Dendreon Corporation Detroit Tigers Michael D. Dingman Ty and Fran Durekas Robert and Tricia Earl Bruce Eichner BlackRock Financial Management William B. Finneran First Data Western Union Foundation Paul M. Fleming Forester Family Foundation Theodore J. Forstmann Freeport-McMoRan Foundation Michael Frey Jerry Friedman Carlos Fuente, Jr. The Gaba Family Foundation Gantcher Family Philanthropic Fund Jeffrey D. Garguilo and Valerie Boyd Arthur and Linda Gelb Jay Geldmacher Russell and Zina Geyser Global Fitness Holdings, LLC Henry and Arline Gluck Stanley P. Gold Jeremy P. Goldberg Richard and Marcia Goldberg Bennett and Meg Goodman John R. and Kiendl Dauphinot Gordon Fund Stephen Gordon John and Kathleen Gorman GPC Biotech Greenbriar at Whittingham John A. Griffin Movado Group, Inc. William and Susan Gross Allen Grubman Norb Guziewicz Clay W. Hamlin, III Alan and Vivien Hassenfeld Sam Herzberg Houston Golf Association Roy W. Howard James Hudson Michael Huffington

Internet Real Estate Group, LLC Jim Beam Brands Co. William P. and Dorian S. Jordan Foundation, Inc. David G. Kabiller, CFA Joseph H. Kanter Foundation Matthew Kaplan Bruce E. Karatz John Kelley Melvyn N. Klein David and Janet Kline Fund The Kobrand Foundation Fred Kolber Timothy Koogle Dewanto Kurniawan Emeril Lagasse Benjamin V. and Linda Lambert Kenneth and Linda Lay Robert E. Linton Ira A. Lipman Los Angeles Angels of Anaheim Los Angeles Lakers Macquarie Bank Limited Laurence and Karen Mandelbaum Bernard Marcus Michael Marek Stanley and Pamela Maron Joseph and Anne McCann John E. McCaw Richard McKenzie, Jr. Jerome Meislin Herman and Susan Merinoff Barry Meyer Millennium Pharmaceuticals, Inc. Michael Minikes Edward J. Minskoff Morongo Band of Mission Indians Nat. Amer. Rights Fund Robert E. Morrow Angelo and Phyllis Mozilo Ken Nees Neiman Marcus Direct NetJets Aviation, Inc. Aviv Nevo New York Mets Foundation, Inc. L. Mark Newman Family Foundation Phil R. North Ruth Ornest Jon Otto The Palin Family Foundation, Inc. Jim Pattison Ethan Penner The Picower Foundation Chris Prezioso Pritzker Foundation Alan Quasha Martin and Patricia Raynes Tony Ressler and Jamie Gertz Richard S. Ressler Meshulam Riklis The Riordan Foundation George R. Roberts The Rose Foundation Andrew M. Rosenfield E. John and Pat Rosenwald Steven and Daryl Roth Eric Rothfeld Peter H. Rothschild Alvin and Marilyn Rush Mike Ryan Ronald S. Saks Ronald Salkow The Mara and Ricky Sandler Foundation Richard J. Schmeelk Allen B. Schwartz Thomas J. Shannon, Jr. Howard P. Shore Mace and Jan Siegel

Harvey L. Silbert, Esq. Jeffrey and Helaine Silverstein Herb Simon William E. and Tonia Donnelley Simon Paul and Celia Sirotkin Stuart M. Sloan Jeff P. Smith Southern California District Council of Laborers Saul P. Steinberg James Stern Sternlicht Family Foundation Louis B. Susman Allan Tessler William H. Tilley Time Inc. Pier Luigi Tolaini Joe and Alice Torre Jeanette Trepp Trimaran Capital Partners Marc and Mindy Utay Clark Van Nostrand Charles J. Wagner Mark R. Walter Alice Walton Cheng Ching Wang Casey and Laura Wasserman Jerry and Jane Weintraub Gary and Nina Wexler David Yandry Don Yannias

Friends ($25,000 to $49,999)

Anonymous (1) A Charity Challenge Don Ackerman Neale M. Albert, Esq. Norman E. Alexander Allchin Foundation Judd Apatow Arby’s Frank J. Arcella Matthew Arcella Roland E. Arnall AstraZeneca Jude T. Barbera, MD David W. Bash, PhD and Judy Oliver-Bash, PhD Candice Beaumont Arthur Becker and Vera Wang Robert A. Belfer Art H. Bilger Les and Sheri Biller Bobby Blair Charles X. Block Bluefish Concierge, Inc. Salvatore and Alison Bommarito Bonita Bay Community David Booth Tony Borhani Boston Red Sox Foundation Denis A. Bovin The Braka Philanthropic Foundation Harry M. Brittenham, Esq. Coco Brown Thomas and Jo Anne Bruno John M. Bryan Brian P. Burns Arthur Byrnes Andrew S. Clare Brian and Denise Cobb Gregory and Monica Coleman David and Courtney Corleto Country Club of Roswell Lester and Renee Crown Edgar and Elissa Cullman Ian M. Cumming Robert and Kelly Day

2009-2010 progress report 15

Celine Dion Foundation Mark Donnelly Michael Dougherty Efficiency Enterprises Harvey P. Eisen Lewis M. Eisenberg Lawrence R. Elins Endo Pharmaceuticals The Entertainment Industry Foundation Thomas J. Fazio Ferolito, Vultaggio & Sons Cary Fields Steve Fink Alex Fisher Peter E. Fleming, Jr. Todd Follmer Theo and Constance Folz Lionel Frais John R. Frank Keith Frankel Jim Freer Robert Fremont Josh S. Friedman Steven Friedman Paul R. Garcia Philip H. Geier, Jr. GNC Stephen and Mindy Geppi Charles and Vivian Gillespie The Honorable Rudolph W. Giuliani GivingCapital, LLC Bruce Goldstein Eric Goldstein Michael Goldstein Litto Gomez Edward and Cheryl Gordon Maureen V. Gorman Fredric Gould John P. Gould Alan C. Greenberg Haarlow Family Charitable Foundation Kenneth B. and Carolyn Hamlet John J. Hannan Reed and Nan Harman William Hartnett Hastings Capital Group, LLC John R. and Lauren Haynie, Jr. Ralph and Kay Hemingway John and Susan Hess Samuel J. Heyman Kenneth and Janet Himmel HLT Prostate Cancer Fund H. S. and Diane Hoffman Charlie J. Horky David S. Howe and Charlene Wang Michael R. Howland Charles and Barbara Hurwitz The Iacocca Foundation IRI Golf Management, LP Jack’s Broken Open Steve and Ellen Jackson Herb W. Jacobs Stanley R. Jaffe Christopher M. Jeffries Joseph Drown Foundation John Kahrhoff Memorial Golf Gerald Katell The Fritz and Adelaide Kauffman Foundation, Inc. Stephen and Marina Kaufman KB Home J. Christopher Kennedy Michael Klein Henry R. Kravis Bill Lane, Jr. Jeffrey & Nancy Lane Foundation, Inc. Gerrity Lansing Bennett and Jerri Lebow

16 2009-2010 progress report

Jerry Lee, Newton Running Company Ken Leese Steve Lehman John S. Levy Linder Charitable Remainder Unitrust Joseph Rob Link Lords Valley Country Club, Inc. Vincent Lorio Los Angeles Dodgers Joe Lumarda Susan E. Lynch Gene E. Lynn Donald and Hilda Lytton David S. Mack Fredric Mack Harvey Mackay Stewart Manheim Howard and Nancy Marks Robert and Joan Masterson Harold Matzner Robert and Marilyn May Keith W. McCaw Michael McKeever Dennis Mehiel Merck and Co., Inc. Harold M. Messmer, Jr. Theodore N. Miller Minnesota Twins Molecular Insight Pharmaceuticals, Inc. Jim Mooney James F. Moore Mark E. Mortimer Stuart W. Moselman John Nickoll T. D. O’Connell Chris K. Olander Pierre and Pam Omidyar Ozaukee Country Club Dean E. Palin Larry R. Palmer Matthew Pisoni William J. Polvino John and Laura Pomerantz Portland Bolt & Manufacturing Steve Posner Post Advisory Group Anthony & Jeanne Pritzker Family Foundation Royce G. Pulliam Mark Quigley Ed W. Rabin Richard E. Rainwater Ramblewood Country Club Joseph Reece Bob Roberts Bill R. Roberts Neal I. Rodin Richard and Barbara Rosenberg Stan and Patti Rosenfeld Round Hill Country Club Andrew Ruotolo Barry L. Rupp Peter M. Sacerdote Foundation David Sambol Richard and Margaret Santulli John H. Schnatter Irving Schneider Michael and Paola Schulhof David and Fela Shapell William Shaw David and Lynn Silfen Mark J. Simon Fred L. Smith Smithburg Family Foundation Irwin and Lorri Spiegel St. Louis Cardinals Fred and Sharon Stein Steinberg Family Fund, Inc.

Spencer Stokes Stricklin Account of Fidelity Charitable Gift Fund Burt and Mary Sugarman Jim Tarlton Douglas P. Teitelbaum William Thompson James Tisch Bruce E. and Robbi S. Toll Foundation Varhegyi Foundation Peter Vegso Michael and Laura Venerable Linda J. Wachner Samuel Waksal Elmer Ward Scobie D. Ward Michael and Jill Weinstein Stephen and Phyllis West Henry Wilf Christopher and Kristine Williams Alexander J. Witherill Douglas Wood Rick Wooley Don Zacharia

Supporters ($10,000 to $24,999)

Anonymous (1) David and Kay Aaker Paul Abecassis Abraham Kaplan Foundation S. Daniel Abraham Abramson Family Foundation, Inc. Joseph P. Adams, Jr. Sheldon Adelson Larry Alleto Alpha Tau Omega Bruce and Elvin Ambler Lee W. Ang Michael F. Armstrong Michael F. Ashby Martha A. Atherton Atlanta Braves Foundation, Inc. Mark and Debbie Attanasio Jerry Auerbach Autism Speaks, Inc. Abraham Azoulay Baby Togs Dan Baldwin Jeffrey and Pamela Balton Martin and Dorothy Bandier Jeffrey C. and Lori Barbakow Sol Barer F. Harlan Batrus Michael J. Batza, Jr. William P. Beatson, Jr. Richard I. Beattie Warren Beatty Gary S. Becker Michael Becker Mitch Becker Allen J. Beeber Alan T. Beimfohr William J. Bell Lee and Susan Benton Eric L. Berg Jeff Berg Anthony Bergamo, Esq. Elliott H. Berger Daniel G. Bergstein David Berkoski The Judy and Howard Berkowitz Foundation Allen J. Bernstein Fred B. Bialek William Bikoff The Black Family Charitable Foundation, Inc. Harvey Blau

Dennis Block Bloomberg Financial Markets Co. Bernt O. Bodal Burton Borman Albert R. Boscov G. Michael Boswell Reggie Bowerman Steve Braverman Bernard and Judy Briskin Broad Street Productions Brooklyn Hospital Center Harry J. Brown Foundation Gloria S. Browning Bryanston Group, Inc. Bulk Truck and Transport Service, Inc. Kurt W. Butenhoff Bernie F. Butler Michael Butler The Capital Group Companies Charitable Foundation Cardean Learning Cardinals Care Michael Caridi Ronald G. Carley Liam Carlos Anthony and Jamie Carr Johnny Carson Donald and Nancy Carter Edwin P. Carter Marx L. Cazenave, II Tom Celani Cell Genesys, Inc. Centocor, Inc. Irwin Chafetz Charity Folks, Inc. Linda Chen Peter Chernin Allen and Jill Chozen Chubb Federal Insurance Company Citigroup The Clark Charitable Foundation H. Lawrence Clark The Clinton Family Foundation Steven Clinton Coca-Cola Co. Harold K. Cohen Mitchell H. Cohen Jim and Marcia Colbert Commerce Bank, North, N.A. Connecticut Baseball Charitable Foundation Jimmy and Patti Connors Nancy and James Cook The David and Sheila Cornstein Foundation Corte Bella Women’s Golf Association Jack B. Corwin Ken Cory Robert H. Cosgriff Terry Cosgrove Cotton Creek Men’s Golf Association, Inc. The Gerald and Daphna Cramer Family Foundation Credit Suisse First Boston Corporation Alberto Cribiore Robert and Mary Ann Cross Cuba Club Chip Cushman Theodore Cutler Cytogen Corporation Dabney/Resnick Imperial Dalio Family Foundation, Inc. John Daly Darling Family Fund J. Morton Davis Marvin and Barbara Davis Roger J. Davis

Michel De Beaumont Delcal Enterprises, Inc. Joseph J. Dempsey Cosmo DeNicola Donald J. Deutsch Deutsche Bank Terry and Marilyn Diamond Dietz & Watson Foundation Richard DiMeola Dinan Family Foundation Don King Productions, Inc. Donaldson, Lufkin & Jenrette Carl Doumani Dow Electronics Milton H. Dresner Foundation, Inc. David H. Dreyfuss Joseph J. Dvorak, Jr. Alvin Dworman Eastdil Realty, Inc. Charles Edelstein Stephen Einhorn David F. Eisner Niko Elmaleh Elmwood Country Club The Engelberg Foundation Roger A. Enrico Mike Ensign Gamma Enterprises, LLC The Daniel J. Epstein Fund of the Jewish Community Foundation Jeff Epstein Evergreen Foundation Eugene and Sallyann Fama Jonathan D. Farkas Federated Department Stores Foundation Jeffrey P. Feingold Brad Felenstein Robert M. Fell James and Alise Ferency Mike Ferry The Diane and Elliot Feuerstein Fund of the Jewish Community Foundation Mark Finerman Gerald B. Finneran Jerome and Anne Fisher Larry and Kathleen Fisher Lester and Gwen Fisher Richard Fisher Dawn N. Fitzpatrick Joseph Flom Florida Marlins Steven T. Florio Jean Fogelberg Lynn Forester Michael G. Foster, Jr. William C. Foster Fred Hutchinson Cancer Research Center Paul Fribourg Friedman Family Foundation Larry H. Friend Peter Fudge Jeffrey Furman Frederick and Peggy Furth Ronald H. Galowich Brian Gamache Michael and Lynn Garvey Arie Genger David H. Glaser Guilford and Diane Glazer Alan and Marlene Gleicher Seth Glickenhaus Colin Goddard, Ph.D. Bradley and Sunny Goldberg Michael A. Goldberg Andy Goldfarb

R. Anthony Goldman Russell D. Goldsmith The Golfworks The Gordon Family Foundation Edward and Cheryl Gordon Berry Gordy, Jr. Abraham D. Gosman Laurence Graff Mark Grant Madison and Susan Graves George D. Grayson George & Reva Graziadio Foundation Steven and Dorothea Green Gary and Sandra Grimes Grizzard Family Foundation, Inc. Julie Groshens Michael S. Gross The Marion and Louis Grossman Foundation H.J. Heinz Company Blair R. Haarlow Roger S. Haber Thomas R. Hagadone and Pam Miller Kerry and Kelly Hagen David and Leslie Hahn Brian L. Halla James A. Harmon Richard J. Harrington Joshua J. and Marjorie Harris Mel Harris William B. Harrison, Jr. Richard C. Hartnack Albert and Irene Hartog Home Box Office Richard J. Heckmann Andrew L. Heiskell Bruce Heller Jane Heller The Helping Hands Sales, Inc. Jerry Hennessy Lawrence Herbert Heritage Operating, LP Leon and Norman Hess Andrew R. Heyer Steven Higger Highlands United Methodist Men Rick Hill Joni Hirsch Blackman The Armin & Esther Hirsch Foundation Douglas Hirsch and Holly Ander Hitching Post Motels Beth Hollfelder Butch Holmes Jane Holzer Homayoun Homampour Steven and Cathy Hooper Houston Astros D. E. Brice Howe HSK Funding Helmut Huber Gene Humphrey Michael Hyatt Royce Imhoff International Financiers, Inc. Invemed Associates, LLC Ironman Motivations Nathan P. Jacobs Sheldon Jacobs Ron Jacoby Robert M. Jaffe Leonard R. Jaskol The JCT Foundation Michael and Linda Jesselson Johnson Bank Clark A. Johnson Allen N. Jones Ellis B. Jones Glenn R. Jones Wayne D. Jorgenson

The Joseph and Ida Foundation Inc. Mitch Julis The Kandell Fund Kansas City Royals Harold Sanford Kant, Esq. Scott G. Kasen Peter M. Kash Howard and Susan Kaskel George Kaufman David and Silvana Kay Joshua and Joia Kazam Dean C. Kehler Gregory F. Kiernan Brian King Michael G. King, Jr. Lila Kingsley Kirkland & Ellis Foundation Joel Kirschbaum Calvin Klein James W. Klein John Kliger Michael and Patricia Klowden KML Golf, LLC Emerson and Peggy Knowles Harold and Shirley Kobliner Jeff Koffman Roger and Lorraine Kotch KPMG, LLC Jules B. Kroll A. B. Krongard Mark Kurland Herbert and Edyth Kurz Lachman Family Foundation LA-CO Industries, Inc. L’Acquisition Corporation Martin and Sheila Lasky Latham & Watkins Leonard and Evelyn Lauder William P. Lauder Steve Lawrence and Eydie Gorme Norman Lear Lederman Family Foundation Don and Rita Lee Schwartz, Kales Accountancy Corp. Stephen R. Leibowitz Alfred and Norma Lerner Julius and Miriam Lesner Frederick N. Levinger Frances and Jack Levy Foundation Richard Levy Loida N. Lewis Robert Lienau Lights Out for Cancer Mrs. Arthur Liman Steven Lipman Michael D. London Lord Abbett & Co. LLC David B. Lowry Rufus and Patricia Lumry Robert G. Lusk LZR Sports, LLC Jerome D. Mack Richard Mack Macy’s John Magliocco Peter A. Magowan Mandalay Resort Group Alan and Barbara Mandelbaum Mandelbaum Foundation Mel Mannion Stephen J. Marcus Mariners Care Morris Mark Howard and Stacy Marks Nancy Marks Maverick Capital Foundation Kenneth Mazik Larry Mazzola Michael and Kristy McChesney

Les G. McCraw, Jr. Jeffrey and Ashley McDermott John and Constance McGillicuddy MCI WorldCom Foundation Thomas J. McKearn Kara McKinley Laureston and Barbara McLellan J. P. McManus James A. McRae Medco Containment Co. Todd Meister Prakash Melwani Arnon Milchan Lee and Sylvie Millstein Milwaukee Brewers Larry A. Mizel Robert Michael Mondavi Charles K. Monfort Eugene Monkarsh David Moore Jacques J. Moore Pete Moore William S. Morris, III Jerry Moss Wayne Mueller Donald R. Mullen Peter Mullin Bill Mundell Hilary Musser Miles Nadal Naples Drive for the Cure The Nash Family Foundation Menasche M. Nass David Nazarian NBS Diamonds, Inc. Marty Nealon Rooney Nelson Blake Lee Neubauer New England Financial New Jersey Basketball, LLC Wayne and Kathleen Newton NFL Charities Perry Nisen Northern California District Council of Laborers Novacea, Inc. Marlene Nusbaum Oakland Athletics Cindy K. Olson Paul, Weiss, Rifkind, Wharton & Garrison, LLP Peter Busch Orthwein Gregory J. and Mary V. Pacelli Chuck Palombini Marvin Parsons Alan Patricof Norman J. Pattiz David Pecker Gerry Pencer Arthur Penn Pensions 2000 Leonard C. Perham Phillips-Van Heusen Foundation, Inc. Phoenix Home Life Mutual Insurance Company Elizabeth Pinsonault Albert and Jeanine Pirro Michael A. Pitino Mack Pogue Carl and Eloise Pohlad Family Foundation The Poses Family Foundation Maury Povich and Connie Chung Michael J. Price William L. Price Wayne Prim, Jr. Jay Pritzker Prometheus International, Inc.

2009-2010 progress report 17

Quiksilver Foundation Harvey and Pauline Radler Sheri and Marc Rapaport Fund of the Jewish Community Foundation Mr. and Mrs. Joseph Rascoff Bruce Ratner Michael Ratner Randolph and Lindsey Read John S. Reed Richard and Marget Reneberg W. Brent and Brenda Rice Denise Rich Robin Richards James S. Riepe Family Foundation Richard A. Rigg Harold W. Ripps Richard K. Robbins Brian L. Roberts Kenn Roberts Ralph J. Roberts Thomas and Mary Alice Roberts W. Scott and Karen Robertson James D. Robinson, III Rodney Strong Vineyards Gerald Ronson Allison Rosen Fredric D. Rosen Paul and Catherine Rosenberger Betsy Ross Byron Roth James Rothstein Michel Roux Michael D. Rudd James Russell Kenneth and Dina Russell Edward B. Rust, Jr. Stephen Ruzow and Donna Karan Steve Sanak Raymond and Helen Sandler Richard Sandor Michael Sandorffy Sylvan Schefler Andrew Scheinman David Schneider Raymond D. Schoenbaum Lewis M. Schott Ian Schrager Joan and Paul S. Schreiber Philanthropic Fund of the Jewish Communal Fund David K. Schulhof Schultz Family Foundation Marvin H. Schur Charles and Helen Schwab Alan D. Schwartz Barry K. Schwartz Family Foundation Ted Schwartz Charles Scott Russell Scott, Jr. Tony Scotti Sebastiani Vineyards, Inc. Security Life Inc. Group Henry Seiden Ivan G. Seidenberg Martin Selig Mike Shad Michael Shapiro Richard and Phyllis Sharlin Shearman & Sterling Howard Shecter Mark Shenkman Robert D. Shipp Boaz Shonfeld Walter Shorenstein Pam Shriver Fund of the Baltimore Community Foundation Stan Shuster Stanley J. Sidel Sanford C. Sigoloff

18 2009-2010 progress report

Eugene Silverman Jay B. Silverman Thomas M. Simms Ted Simpkins Sirens Society Sanford Sirulnick John and Cindy Sites Charles B. Slack Alan B. Slifka Lynn Smiledge John F. Smith, Jr. Matthew and Tracy Smith Orin Smith Snyder Weiner Weltchek & Vogelstein Marilyn Sobel Bruce Sokoloff Bob Solomon Warren J. Spector Allison Speer Aaron and Candy Spelling Jerry Speyer The Jerry and Emily Spiegel Family Foundation Lawrence Spira Sports Licensed Division of the Adidas Group, LLC Starkey Sports Consulting, LLC The Starr Foundation Joseph Stein Jeffrey Steiner Irving Stenn, Jr. Karl Sternbaum Gary Stoneburner Michael Strauss Lawrence Sheldon Stroll Melanie Sturm Marianne Sufrin Sanford and Charna Sugar Sunbelt Beverage Company, LLC Sunrise Rotary Foundation Katharyn Swintek Tag Associates, LLC Roberta R. Tanenbaum Tanger Factory Outlet Centers, Inc. Edward Taran Jeremiah and Nonie Tarr Stanley G. Tate Fredricka Taubitz Ian Ross Taylor Robert Taylor Teleflora, LLC Anthony Terlato Terravita Golf Club, Inc. Texas Propane Gas Association T. F. Trust Charles and Adele Thurnher Steve Tino Andrew H. and Ann Tisch Daniel and Bonnie Tisch Steven H. Tishman Dennis A. Tito John T. Toland Richard P. Torykian, Sr. Jesse I. Treu Prabhakar Tripuraneni The Trump Organization Tudor Investment Corporation Robb & Elizabeth Tyler Foundation, Inc. Valquip Corporation Karen van Nouhuys Mari and Ash Vasan Mary T. Venable Stephen and Laurie Vogel The Vons Companies Charitable Foundation, Inc. Rosemary Vrablic Don Vultaggio Benjamin A. Wade

Shirlene A. Wainer William and Claudia Walters Kenneth Wang William and Sharon Ward Tom Watkins Scott Watt Armond Waxman Robert F. Weis Melvyn I. Weiss Morris Weissman Whittemore Family Foundation Ralph and Wendy Whitworth Arthur Wiener Andrew Wise Fred Wolf Douglas J. Wood C. Tal Wooten, Jr. Leah Wurzberger Young Presidents Organization Los Angeles Chapter Gerard Yvernault Louis G. Zachary, Jr. Harriet Zaretsky Jeffrey Dunston Zients Ron Zimmerman Roy Zuckerberg Robert A. Zummo Sergio Zyman

Contributors ($5,000 to $9,999)

Anonymous (1) 12th Man Foundation Robert J. Abt The Adams Family Charitable Fund Addison Reserve The Adler Family Foundation, Inc. Advance Shared Services Center AIECA of America, Inc. AIM Management Group Alvin R. Albe, Jr. Ellis J. Alden Richard L. Alderson R. Jack and Beulah Alexander Donald and June Alford Allied Beverage Group, LLC Arthur G. Altschul, Jr. Ellsworth C. Alvord, III Richard W. Alvord American Endowment Foundation Ameripoint Foundation John Angelo Terry Anthony Kenneth and Diane Aretsky Tom Armstrong Arris Interactive, LLC Phillip Asherian Michael Ashkin Sherrell Aston Victor K. Atkins David and Elisangela Aufrecht Ralph H. and Susan August Margaret and Edward Augustine Aureon Laboratories, Inc. Rick G. Avare Bacardi Limited Roland and Beverly Bacci David and Michelle Bach Baltimore Orioles Scott P. Barasch Paul and Norma Barash Alexander E. Barkas and Lynda Wijcik Janice Barney John R. Barney The Barrack Foundation Tyler Barth Charles T. Bauer Ted Baum

The Baupost Group, LLC David I. Bavar Beacon Hill Country Club Lee Beattie Jack M. Beaven Fred Bedard Bradley Bell John Bendheim The Frances & Benjamin Benenson Foundation Walt L. Bent Philip J. Bergan Martin S. Berger Stephen Berger Richard Berkowitz Leonard H. Bernheim, Jr. Anthony J. Bettencourt William C. Bevins Les Bider Elliot and Susan Black Marc Blackman Robert S. Blank Michael and Nina Blechman Tim Blixseth James A. Block Ron Boeddeker Franklin Otis Booth, Jr. Kurt T. Borowsky Richard Boughner Boustead Family Foundation, Inc. Larry Bowman Thomas S. Bowman Leonard Boxer Thomas and Janine Braman Breast-Prostate Cancer Benefit at SWCC Thomas Breitling Stephen M. Brett Pete Briger Pam Brill Nancy Brinker Gary Briskman F. James Brock Edward Brodsky Jeffrey P. Brown Richard A. Brown Sam Brown Christopher H. Browne Richard C. Browne C. Kenneth Brumit Marc R. Brutten Deborah L. Burger, Inc. Alan A. Burgess William and Elizabeth Burroughs Jack Burstein Richard Byrd Richard J. Byrne Roger and Mary Campbell Cancer Awareness Gold at Heritage Eagle Bend Canoe Brook Golf Shop Phil Caputo James A. Cardelli CARE William M. Carson S. Ward and Roxanne Casscells, III Frank L. Cassidy, Jr. Matthew J. Celozzi, II Chajet Family Foundation Michael J. Charles Sophie Chen Bernd Chorengel Clarium Capital Management, LLC Greg Clark John H. Claster Cleveland Cavaliers CMA Consulting Services Bert Cohen Joseph M. Cohen

Karen B. Cohen Foundation, Inc. Richard D. Cohen The Betsy and Alan Cohn Foundation, Inc. Victor A. Cohn Mary and Robert Colgan Collington Transportation Golf Outing William S. Comanor Kerby and Judith Confer Connecticut MSBL Michelle A. Connelly Elaine Terner Cooper John Cooper, Jr. Stephen A. Cooper Peter Coors The Copses Family Foundation Corinthian Colleges, Inc. Fred Corrado Marshall B. Coyne Cresa Partners Cullasaja Club, Inc. Gregory Cuneo Cunningham Security Systems Cushman & Wakefield Billy Davis, Jr. Marion J. Davis, Jr. Peter and Julie Dawson Ed DeBartolo, Jr. Paul R. Del Rossi Delaware North Companies, Inc. Jerry Della Femina Dodger Dream Foundation, Inc. Robert Dodson Drexel University, College of Medicine Drexel University William E. Dreyer Daniel A. Duc Duch Family Fund of the Community Foundation of New Jersey Raymond Duncan Prince E. Eagilen Eagle Watch Ladies Golf Association J. C. Earle Family Fund Walter Eberstadt Spencer F. Eccles David B. Edelson Daniel D. Ederer Maurits E. Edersheim Anders B. Eklov Richard and Gail Elden Robert Englander Yan Erlikh Aaron R. Eshman Linda Evangelista Peter Evans William F. Evans Samer Farah Andrew Farkas John Farnsworth Farrell Family Foundation Michael S. Fawer Stanley M. Feingold Irving Feintech Rajiv Fernando Frank and Victoria Fertitta David Fillmore Gregory Fischbach Siegfried and Doris Fischer Richard B. Fisher Stephen B. Fiverson Dennis Flatt Donald Folgner Robert Forbes Sam Forman Gayle Devers Fortune David Foster Fox Hill Country Club Michael F. Frankel Franklin Country Club

Albert Fried, Jr. Joel Friedland Robert and Ann Fromer Front Line Management Group, Inc. Roy Furman Tom W. Gamel Howard L. and Judie Ganek Philanthropic Fund Lloyd Garver Lucio Dallla and Marta Gasperina Frank Gehry Alan Gelband Gelfand, Rennert & Feldman, LLP Georgetown Tobacco & Pipe Stores, Inc. S. William Gersten Michael F. Gilligan, Jr. Tom Giovanelli David Glass Arthur M. Goldberg Howard Goldenson Steve A. Goldfarb Kenneth N. Goldman David and Renee Golush Jan Goodman Bradford S. Goodwin Richard Goodwin Todd Goodwin Jerome S. Gore Louis and Nancy Grasmick Jim Grau Jerry and Barbara Greenbaum Charles H. Greenberg Mark Greenhill Robert W. Greenman, Jr. Bill Greer Dennis M. Griffin Robert Grossman GSI Commerce Howard R. Gurvitch Lynn M. Haff John Hagestad Hall Dickler Kent Goldstein & Wood, LLP Bryan Hallman The Hallman Foundation Jesse Halperin Fred Hameetman William and Vicki Hamilton Mark S. Handler Mark S. Hanson Martin Aaron Harmon Gilbert W. Harrison Lauren M. Hartman Edward J. Hawie Jerry and Marilyn Hayden Kenneth and Kathryn Henderson Thomas S. Henderson and Sally S. Henderson Foundation Arthur Hershaft Michael B. Hershey Edward and Gaye Hewson David Hicks The Hill Family Charitable Foundation Roderick Hills Leslie Wohlhan Himmel Richard Hise Peter A. Hochfelder Robert W. Hoke Richard Scott Hollander Mark Holowesko Vincent Horcasitas Gerald Horowitz John and Sandra Horvitz Thomas J. Howa Joe Howe Harry and Elsie Huber Mark Hughes Wayne Huizenga

James Husband George Hutchinson Arthur I. Indursky Institute for Health & Productivity Management Integrated Health Campus Hale S. Irwin Steve Iverson Jeremy Jacobs Max Javit Jefferson University Gordon W. Jenkins Charles Jennings Daryl L. Jesperson Jewish Federation of Greater Phoenix JFD / MJD Golf Open James and Lorene Jimmerson Alastair J. Johnston The J.P. Morgan Chase Foundation Kaiser Permanente Jay Kaiser Peter S. Kalikow Thomas J. Kalinske Adam Kalish Bruce and Jeanie Kaminsky Walter Karabian Eric P. Karros Stanley Katz Stephen Katz Ivan Kaufman Ronald S. Kaufman Ilan and Linda Kaufthal Richard and Suzanne Kayne Gershon Kekst Donald H. Keltner Ken Roberts Company Jeff & Erica Keswin Family Foundation Keys Foundation Kidz, LLC Jerry King Kirk and Kathleen Knous Burton Koffman Eric D. Kogan Oswaldo Kosta Robert Kraft Orin S. Kramer Norman D. Kurtz John and Kay Kyle Laborers’ International Union of El Monte-Local 1082 Laborers’ International Union of N. America-Local 300 Laborers’ International UnionLocal 270 Constance C. and Linwood A. Lacy, Jr. Foundation Fred S. Lafer Robert F. Lampe, Jr. Robert Larner Ronald Lauder Lynn M. Leany Frank Leanza Charles E. Leonard, III Steve Leonard Warner LeRoy Margaret Lesher John and Betty Levin Neil Levine Dan and Stacey Levitan David Levy Laurence R. Levy Edward Lewis David Liebowitz Sio Lindner Samuel S. Lionel Jeffrey and Susan Liss The Loa Productions, Inc. The Arthur Loeb Foundation

John L. Loeb, Jr. Florian J. Lombardi Foundation Shumer Lonoff Bob Lorsch Douglas and Nancy Lowe Lyncar Enterprises, Inc. Tom Wallace Lyons Gordon Maahs Harry Macklowe James and Gail Maclin John Magnier Anthony J. Magro Brian A. Maki Idelisse Malave Judd Malkin Shareef Malnik George J. Maloof Susan Mandelbaum Alan and Nancy Manocherian Manowitz and Drillings Family Foundation Philip and Marcia Marcus Bernard A. Marden Ken Martin Kim Martindale Elliott Masie Norman and Joanne Matthews Giacomo Mattoli Caryn Mautner Max Performance, LLC Thomas and Musa Mayer James N. McCoy Foundation Richard E. McCready Foundation Fund of the Baltimore Community Foundation Liam E. McGee John S. McIlwain Don McNamara Robert J. McNulty Bryan and Cynthia McWeeney Rolf Meijer-Werner The Melville Foundation Merrill Lynch & Co. Foundation, Inc. Leroy Merritt The Morris and Helen Messing Foundation Dorothy Phillips Michaud Charitable Trust Dwayne Middleton David A. Miller Michael and Laura Miller Honorable Robert Joseph Miller Sherman R. Miller, IV and Mary Sullivan The Litwin Foundation, Inc. Thomas K. Miller MillerCoors, LLC Peter H. Mills Phillip S. Mittelman Alan Mnuchin Arthur and Patricia Modell James J. Moglia David Moore Raymond Moore The Mr. October Foundation for Kids Morongo Band of Mission Indians Morton’s Restaurant Group Judy Bardugo and Harve H. Mossawir, Jr. Paul Motenko Charles H. Mott Joseph M. Murphy Alan C. Myers Douglas P. Nation NBA Properties, Inc. Renato Negrin Lee S. Neibart Craig T. Nelson Mary-Rose Nelson

2009-2010 progress report 19

Nestle Waters North America, Inc. Shilom Neuman Chuck Nicolette Niebaum-Coppola Estate Winery James B. Nish Robert Noelke Douglas and Nancy Norberg Greg Norman John and Maryann Norris North Atlanta National Bank Jonathan R. Novak NHSU Foundation Obermeyer Asset Management Company James T. O’Brien Morris Offit John O’Hurley Marvin Olshan Shepard Osherow Dan Otter John Paffenbarger Donald P. Pakosh Norm Pappas J. Douglas and Marian Pardee Donald J. Parmet Charles A. Partain Partners Marketing Group Rafael Pastor Thomas J. Patrician E.H. Patterson Frances B. Paulsen Randall Eric Paulson Clay Pecorin Elsie Pecorin David R. Pedowitz Pelican Preserve Golf Robert F. Pence James C. Pendergast The Peninsula Club Pennsylvania Breast Cancer Coalition Bruno and Nichola Perillo Mark Perlbinder Charles Persico James L. Peters Robert E. Petersen Pharmaceutical Research and Manufacturers of America Philadelphia Insurance Companies Phillies Charities, Inc. Cynthia H. Polsky Gerald Porter Timothy N. Poster Melvin and Barbara Powell Rick Powell Ed Prager Arlen I. Prentice Richard E. Previdi Wayne Prim, Sr. Edward Probyn Bob Pryt John A. Ptak William and Melody Purdy Kjell H. Qvale Mark Rachesky Robert E. Racicot Steve Rader Raley’s Gold Rush Classic Max Ramberg Raymond Cristobal Memorial Fund, Inc. Donald Rechler Scott Gregg Rechler Joseph P. Riccardo Blair & Kristin Richardson Foundation Ritz-Carlton Boston Ritz-Carlton Chevy Chase Lee P. Rizzuto Linda G. Robinson Sam Robson

20 2009-2010 progress report

Iber Rodriguez Sig Rogich Jeffrey Rosenthal Beth and Peter Rosenthal Memorial Fund, Inc. Stephen M. Ross Gordon Roth Edward F. Rover Royals Charities Richard and Amy Ruben Howard Rubin Mariano A. Rubino Stephen and Cheryl Rush Sheryl Lee Russo and Eva G. Guajaro Denny Ryerson Thomas L. Safran Saul and Evelyn Salka Max and Janet Salter San Diego Padres Allan C. Sanders Theodore and Alison Sands Sandy Spring Bank Jill and Ronald Sargent Patrick Savin Saybrook Tax-Exempt Advisors, LLC Randall H. Scarlett Anthony Scavo, Jr. Al Scheid Schmertz Company, Inc Alfons J. Schmitt David M. Schoenthal Marvin I. Schotland Robert Schulman Gerald M. Schuster Homer R. Schwartz Governor Arnold Schwarzenegger and Mrs. Maria Shriver Lisa White Schweitzer Peter W. Schweitzer Spencer and Jacqueline Segura Michael E. Seiff Richard M. Seigel Sellers Publishing, Inc. Shadow Wood Country Club David M. Shaffer Michael S. Shannon Carl and Ruth Shapiro Family Foundation Robert F. Shapiro Stephen Shechtma Thomas and Madeleine Sherak The Shidler Family Foundation Herbert J. Siegel William Siegel Adrianne W. Silver Richard Silverman Ronald A. Simms David Simon Dick Simon Mimi Simoneaux Jonathan and Plum Simons James D. Sinegal Van Skilling Joel E. Smilow Gordon Smith Jeff N. Smith Arnold Snider Steve Snyder Mr. and Mrs. Stuart M. Solomon James Soules Southern Company Services, Inc. Southern Wine & Spirits of Nevada, Inc. Larry Spitcaufsky Richard and Ellie Sprague The Sprenger Lang Foundation Frank P. Stagen Stak Design, Inc. Starbucks Coffee Company

John Stark Steven E. Stern The Stone Family Fund Tom and Bonnie Strauss William W. Stuart Chris Stuhmer Thomas R. Sturges Fred and Judith Sullivan Mary M. Sullivan Suns Legacy Partners, LLC Dennis A. Suskind Don Swirnow S. Jerome and Judith Tamkin Rica F. Tarnoff Jeffrey Tarr Janie C. Tarter Walter D. Tearse Vincent Tese Andrew Thomka-Gazdik Chuck B. Thornton, Jr. The Laura Steinberg Tisch Foundation, Inc. Tom Tisch TJH Stephen G. Tolchin James E. Tolson, Jr. Thomas Tonko Eugene and Judith Toombs Stanley S. Trotman, Jr. Cecily Truett Mark Truitt Trump Administration Jeffrey H. Tucker Tuesday’s Children Turner Broadcasting System, Inc. UBS AG Peter V. Ueberroth William D. Unger Unified Grocers United Jewish Foundation of Metropolitan Detroit United Way of Greater Los Angeles Tom Unterman Michael J. Urfirer Neil G. Van Luven Basil K. Vasiliou The Daniel Veloric Foundation Velos Medical Informatics, Inc. Mary E. Venable The Villages Robert and Judy Waller David E. Walters John Walton Jack L. Warner Roger Weber Martha Weckel Raymond J. Weis Robert Weiss Jay Weitzman Wheels, Inc. Miles D. White Jeffrey S. Wilks Kenneth and Nancy Williams Gary L. Wilson Daniel P. Wimsatt Wolff Family Foundation The Liberal Do-Gooder Foundation Moira Wolofsky Wolters Kluwer Health Kenneth R. Woods Working Assets Rodney A. Wray Robert A. Yawitt Bud Yorkin Young Presidents Organization Rebel Chapter Gary A. Young Zenkel Foundation Stan Zicklin


Robert C. Atherton Joseph DeVito Bernie and Ralph Dunnigan Estate of Dennis Shea Bruce Moore Goedde Olin Howser Bruce Alan Hupfer Memorial The Estate of Corbin Page Edward M. Piluso Edward F. Sulesky Estate

Champions for a Cure

Nick Adcock Andrew Akiyoshi Max Andes Sal Augeri The Baggio-Millstein Wedding Gareth Barlow Ray Bayat Peter Binks Erlend Bo Michael Cameron Damien Clark David S. Deschenes Jeff Dorman Scott Duxbury Fans of Dan Fogelberg Matthew Friend Kimberly Fry Blair R. Haarlow Brandon Haley Matthew J. Hoffman Carlo Huber S. Andrew Katz David Kimmel Emerson T. Knowles Scott Kolasinski Gideon Lang-Laddie Ryan Link Jeffrey Maddox Brett Matik Ray Mays Bob McKnight Sherman R. Miller, IV Casey Nelson Ryan Nelson Joseph Nuzzarello Nick O’Kane Rob Parker Ian Parmiter Propane Industry Pros4Care Andy Petranek Steve Rakow George R. Reinhardt Pete Ridge Will Rutledge Kelly Slater Karen Smyers Neal Thompson Brett J. Troia Steven Trussell Team Winter Rebecca L. Vozzo Jamie Weisman John M. White Matt Woehnker John Yodzis Pam Zam

Represents cumulative donations as of December 31, 2009.

EVENTS FOR CURES Each year, PCF benefits from events that provide an opportunity to communicate PCF’s mission, support awareness for the cause and raise funds for research. These events provide our supporters with a broad range of opportunities to get involved for cures.

Clockwise from top left: PCF’s 2009 New York Dinner, featuring David Foster and Andrea Bocelli, raised more than $4 million for research and eight new Young Investigators • Major League Baseball’s 2010 All-Star 5K and Fun Run featured more than 9,000 participants and raised $50,000 • More Mo’ Bros and Mo’ Sistas are joining the fun each “Movember,” celebrating moustache growth for research. To date, Movember has raised more than $2.5 million for research • PCF’s annual Home Run Challenge brought our message to baseball fans across the country and raised almost $2 million from pledges in 2010 2009-2010 progress report 21

Appeal for support

Dear Friend, With recent breakthroughs in research, prostate cancer is at an historic turning point and we are closer than ever to eliminating death and suffering from this disease that affects more than 2.5 million American men and their families. This rate of progress would be unsustainable without your ongoing support. Your investment in the Prostate Cancer Foundation is carefully deployed. Since 1993, virtually every important discovery in the battle against this disease has been stimulated and fast-forwarded by PCF funding or coordination. Moreover, every dollar you contribute to PCF is multiplied 20 to 30 times. Our activities set into motion a ripple that spurs research at government, biopharma and charitable institutions and, in effect, leverages the millions of dollars we raise into billions. This past September in Washington, D.C., shoulder to shoulder with our partners in the prostate cancer community, we asked our nation’s leaders to rededicate themselves to scientific innovation and achieve freedom from prostate cancer through increased research funding and enhanced support services for men who are diagnosed. Your continued generosity is still urgently needed so we can continue the momentum we have achieved and realize our ultimate goal—the end of prostate cancer as a lethal disease. On behalf of patients, families, caregivers and our research scientists around the world, we appreciate your support and ask that you give now so PCF can “turn off the lights” soon. With deepest gratitude and wishes for good health,

Jonathan W. Simons, MD President and Chief Executive Officer David H. Koch Chair

22 2009-2010 progress report

donation opportunities The Prostate Cancer Foundation welcomes gifts of cash, securities, non-cash assets and gifts by will or living trust. We also welcome contributions made in memory, in tribute or in honor of friends or loved ones.

Challenge Awards ($1,000,000+)


PCF supports transformational prostate cancer research to accelerate progress toward the reduction of death and suffering due to advanced prostate cancer.

Please mail your check to:

Teams may be assembled from one or several institutions and should include at least three investigators capable of providing unique scientific expertise to the solution of a significant problem in prostate cancer research. Ranging from $300,000 to $1,000,000 per year for three years, these awards will cover direct costs of the research.

Creativity Awards ($300,000) PCF supports innovative and daring research with Creativity Awards. Paid over a two-year period, these awards totaling $300,000 support exceptionally novel projects with great potential to produce breakthroughs for detecting and treating prostate cancer. They are complementary and integrated with other PCF award programs.

Young Investigator Awards ($225,000) PCF provides these three-year awards, totaling $225,000, to keep the field of prostate cancer research vibrant with new ideas. The awards, matched by recipients’ institutions, offer career and project support for young but proven investigators (35 years or less) who are committing their lives to a cure for prostate cancer.

Prostate Cancer Foundation 1250 Fourth Street Santa Monica, CA 90401 To make an online contribution, please visit our website: If you prefer, you can make a donation by phone by calling toll-free (800) 757-CURE (2873).

Memorial or Tribute Gifts • Honor the memory of a loved one or celebrate the accomplishments of a friend or family member by helping others • Make a memorial or tribute gift and PCF will send an acknowledgement card to the family or honoree

Monthly Giving • Set up recurring donations for a convenient and manageable gift process that fits your monthly budget

Other Gift Suggestions • Assets or property including appreciated stock and real estate • Bequest – remember PCF in your will • Name PCF as the primary or contingent beneficiary on a life insurance policy For more information, visit

2009-2010 progress report 23

Prostate Cancer Foundation

Statements of Financial Position December 31



Assets Current assets: Cash and cash equivalents $ 30,510,823 $ 27,894,591 Pledges receivable 6,334,109 4,043,333 Marketable securities 51,968 25,312 Prepaid expenses 58,523 80,497 Other receivables 120,547 – Total current assets 37,075,970 32,043,733 Furniture, equipment and improvements: Furniture and fixtures Office equipment Leasehold improvements Computer software

37,180 210,672 246,891 385,464

37,180 110,574 246,891 344,384

Less accumulated depreciation

880,207 (688,415)

739,029 (606,244)

Investments Long-term pledges receivable Total assets

191,792 132,785 560,000 960,000 2,086,917 2,772,772

$ 39,914,679

$ 35,909,290

Liabilities and net assets Current liabilities: Accounts payable $ 130,614 $ 76,830 Accrued liabilities 309,588 953,057 Accrued payroll and payroll-related liabilities 573,438 424,103 Research awards payable 13,238,378 10,356,378 Total current liabilities 14,252,018 11,810,368 Long-term research awards payable Total liabilities



17,367,018 19,916,745

Unrestricted net assets 22,547,661 15,992,545 Total liabilities and net assets

24 2009-2010 progress report

$ 39,914,679

$ 35,909,290

Prostate Cancer Foundation

Statements of Activities December 31



Support and revenues: Donations $ 33,265,074 $ 36,720,708 Net realized and unrealized loss on investments (415,074) (3,805) Interest and other income 329,244 520,254 Total support and revenues 33,179,244 37,237,157 Program services: Research grants, association awards and donations 15,153,848 28,069,538 Scientific conferences 2,059,200 2,086,024 Public awareness and advocacy expense 2,194,062 2,529,047 Total program services

19,407,110 32,684,609

General and administrative expenses Fund-raising expenses

2,714,456 2,887,230 4,502,562 4,403,510

Total expenditures 26,624,128 39,975,349 Increase (decrease) in net assets

6,555,116 (2,738,192)

Net assets at beginning of year 15,992,545 18,730,737 Net assets at end of year

$ 22,547,661

$ 15,992,545

2009-2010 progress report 25

Prostate Cancer Foundation

Statements of Cash Flows December 31 Operating activities Increase (decrease) in net assets





$ (2,738,192)

Adjustments to reconcile increase (decrease) in net assets to net cash provided by operating activities: Depreciation and amortization Donation of marketable securities Net realized and unrealized loss on investments Proceeds from sales of marketable securities Changes in operating assets and liabilities: Pledges receivable Marketable securities Prepaid expenses Other receivables Accounts payable Accrued liabilities Accrued payroll and payroll-related liabilities Research awards payable

(1,604,921) 862,649 (26,656) (1,057,545) 21,974 (21,281) (120,547) 50,564 53,784 (289,705) (643,469) (109,955) 149,335 (59,745) (2,109,377) 9,812,755

Net cash provided by operating activities

2,757,410 6,638,433

82,171 (399,533) 415,074 384,459

63,787 (116,462) 3,805 237,758

Investing activities Purchase of furniture, equipment and improvements



Net cash used in investing activities



Net increase in cash and cash equivalents 2,616,232 6,619,329 Cash and cash equivalents at beginning of year 27,894,591 21,275,262 Cash and cash equivalents at end of year

26 2009-2010 progress report

$ 30,510,823

$ 27,894,591

Prostate Cancer Foundation

Report of Independent Auditors

Board of Directors Prostate Cancer Foundation We have audited the statements of financial position of Prostate Cancer Foundation (the Foundation) as of December 31, 2009 and 2008, and the related statements of activities and cash flows for the years then ended. These financial statements are the responsibility of the Foundation’s management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States and the standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Foundation’s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Foundation at December 31, 2009 and 2008, and the changes in its net assets and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States.

August 27, 2010

2009-2010 progress report 27

PARTNERS FOR PROGRESS PCF is grateful for the support of our Partners for Progress. These organizations’ major contributions and campaigns are enabling PCF to move closer to our goal of realizing a world without prostate cancer.

Platinum Partners


Supporting Partners


Biotechnology & Pharmaceutical Partners

28 2009-2010 progress report

BOARD OF DIRECTORS & LEADERSHIP TEAM Board of Directors Michael Milken

Founder and Chairman Prostate Cancer Foundation

Charles F. Baird, Jr. Managing Partner North Castle Partners

J. Darius Bikoff

Leadership Team Peter T. Grauer

Lori Milken

The Reverend Rosey Grier

Jerry Monkarsh

Chairman Bloomberg, LP

The Milken Family Foundation

Stuart Holden, MD

Vice President Prostate Cancer Foundation Partner EJM Development

Founder The Observatory US, Inc.

Director, Louis Warschaw Prostate Cancer Center Cedars-Sinai Medical Center

Henry L. Nordhoff

James C. Blair

Arthur H. Kern

Lynda Resnick

General Partner Domain Associates

Steven A. Burd

Chairman, President and Chief Executive Officer Safeway, Inc.

The Honorable S. Ward Casscells, MD

John E. Tyson Distinguished Professor of Medicine and Public Health, and Vice President for External Affairs and Public Policy University of Texas Health Science Center at Houston

David A. Ederer

Chairman Ederer Investment Company

David J. Epstein

Founder ACS Clearinghouse

R. Christian B. Evensen Managing Partner Flintridge Capital Investments, LLC


David H. Koch

Executive Vice President Koch Industries

Richard S. LeFrak

Chairman, President and Chief Executive Officer The LeFrak Organization

The Honorable Earle I. Mack Senior Partner The Mack Company

Jeffrey A. Marcus Managing Director Crestview Advisors

Shmuel Meitar Director Aurec Group

Leslie D. Michelson

Chief Executive Officer Private Health Management

Vice Chairman The Shipston Group Vice Chairman Roll International

Bert C. Roberts, Jr.

Jonathan W. Simons, MD President and Chief Executive Officer David H. Koch Chair

Ralph Finerman

Chief Financial Officer, Treasurer and Secretary

Gary Dicovitsky

Executive Vice President Development

Howard R. Soule, PhD

Executive Vice President and  Chief Science Officer

Consultant BR Ventures

Stuart Holden, MD

Richard V. Sandler

Jan Haber

Vice President Maron & Sandler Executive Vice President Milken Family Foundation

J. Gary Shansby

Chairman Partida Tequila, LLC

Lawrence J. Stupski Chairman Stupski Foundation

Stanley R. Zax

President and Chairman Zenith National Insurance Corp.

Medical Director

Vice President Events, Donor Relations

Helen Hsieh

Vice President Finance and Administration

Dave Perron

Vice President Baseball and Sports Enterprises

Jan Wolterstorff

Vice President Movember Initiatives

Dan Zenka, APR Vice President Communications

EJ Milken

Co-Founder Milken Institute Young Leaders’ Circle

PCF’s research and outreach progress provides an important base for accelerating the end of suffering from prostate cancer.

1250 Fourth Street, Santa Monica, CA 90401  Tel 800.757.CURE (2873)  Fax 310.570.4701

Cert no. SCS-COC-001345